Company Overview and News

Spotlight On Gambling Reset And Banking Bill

18h seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.

AmInvestment retains ‘buy’ call on Prestariang

PETALING JAYA: Prestariang Bhd could record a 25% growth in the company’s software management revenue from the replication of the master licensing agreement (MLA) contracts with other prominent software partners such as Adobe and IBM, says AmInvestment Research.

Insider buying by directors eases to HK$118 million for the week

2017-07-16 scmp
Notebable buying activity took place in Chinasoft International and Colour Life Services Group, while insider sales were recorded in Shenzhen International Holdings

Tencent co-founder takes lead in HK$900m Chinasoft fundraising

2017-04-19 scmp
Chinese philanthropist Charles Chen Yidan, the retired co-founder of internet giant Tencent Holdings, is looking to expand his portfolio of technology, media and telecommunications investments through the latest fundraising initiative of Chinasoft International.

ChinaSoft first half revenue up 21pc on IT outsourcing growth

2016-08-23 scmp
Huawei Technologies-backed software and information services provider ChinaSoft International posted a 20.8 per cent year-on-year rise in interim revenue on growth from core customers and contributions from its information technology outsourcing platform Joint Force.

Chinasoft Announces 2015 Annual Results: Net Profit Increased 40% YoY

2016-03-21 prnewswire
BEIJING and HONG KONG, March 21, 2016 /PRNewswire/ -- Chinasoft International (hereinafter referred to "Chinasoft" or "the Group") (SEHK:354) announced its audited 2015 financial results.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...